← Back to Screener
Centessa Pharmaceuticals plc American Depositary Shares (CNTA)
Price$39.86
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)28.44%
Price vs S&P 500 (4W)-4.49%
VGM Score79.75
Market Capitalization$6.16B
All Metrics
Book Value / Share (Quarterly)$2.24
P/TBV (Annual)1.96x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.35
Price vs S&P 500 (YTD)48.04%
EPS (TTM)$-1.77
10-Day Avg Trading Volume0.96M
EPS Excl Extra (TTM)$-1.77
EPS (Annual)$-1.46
ROI (Annual)-31.01%
Cash / Share (Quarterly)$1.83
ROA (Last FY)-28.73%
EBITD / Share (TTM)$-1.82
ROE (5Y Avg)-60.40%
Cash Flow / Share (Annual)$-1.07
P/B Ratio12.64x
P/B Ratio (Quarterly)12.61x
Net Income / Employee (Annual)$-1,674,000
Net Interest Coverage (TTM)-29.86x
ROA (TTM)-44.17%
EPS Incl Extra (Annual)$-1.46
Current Ratio (Annual)8.57x
Quick Ratio (Quarterly)9.33x
3-Month Avg Trading Volume2.24M
52-Week Price Return204.21%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.66
P/S Ratio (Annual)410.65x
Asset Turnover (Annual)0.02x
52-Week High$40.26
EPS Excl Extra (Annual)$-1.46
26-Week Price Return44.37%
Quick Ratio (Annual)8.31x
13-Week Price Return48.52%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)9.53x
Enterprise Value$6.21B
Revenue / Employee (Annual)$127,100
Pretax Margin (Annual)-1304.75%
Cash / Share (Annual)$3.64
3-Month Return Std Dev92.54%
Net Income / Employee (TTM)$-2,124,100
ROE (Last FY)-37.49%
Net Interest Coverage (Annual)-32.36x
EPS Basic Excl Extra (Annual)$-1.46
Total Debt / Equity (Quarterly)0.23x
EPS Incl Extra (TTM)$-1.77
ROI (TTM)-47.73%
Revenue / Share (Annual)$0.11
Tangible BV / Share (Annual)$3.54
Price vs S&P 500 (52W)176.00%
Year-to-Date Return58.98%
5-Day Price Return0.03%
EPS Normalized (Annual)$-1.46
ROA (5Y Avg)-44.15%
Net Profit Margin (Annual)-1316.88%
Month-to-Date Return0.86%
Cash Flow / Share (TTM)$-1.64
EBITD / Share (Annual)$-1.52
Operating Margin (Annual)-1384.61%
LT Debt / Equity (Annual)0.21x
ROI (5Y Avg)-49.21%
LT Debt / Equity (Quarterly)0.23x
EPS Basic Excl Extra (TTM)$-1.77
P/TBV (Quarterly)2.54x
P/B Ratio (Annual)6.31x
Book Value / Share (Annual)$3.03
Price vs S&P 500 (13W)38.78%
Beta1.09x
Revenue / Share (TTM)$0.00
ROE (TTM)-60.37%
52-Week Low$10.95
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.52est. -0.40
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.32
4.05
3.68
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CNTACentessa Pharmaceuticals plc American Depositary Shares | — | — | B | $39.86 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company with a portfolio of therapeutic candidates across multiple disease areas. Key programs include SerpinPC for hemophilia, LB101 for solid tumors, ORX750 for narcolepsy and sleep disorders, and MGX292 for pulmonary arterial hypertension, plus an undisclosed solid tumor program.